Novartis (Bangladesh) Limited
Novartis (Bangladesh) Limited, a subsidiary of the global healthcare leader Novartis AG, is headquartered in Dhaka, Bangladesh. Established in 1994, the company has made significant strides in the pharmaceutical industry, focusing on innovative medicines and healthcare solutions. With a strong presence in major operational regions across Bangladesh, Novartis is dedicated to improving patient outcomes through its diverse portfolio. The company’s core products include prescription medications in areas such as oncology, cardiology, and immunology, distinguished by their cutting-edge research and development. Novartis (Bangladesh) Limited has earned a notable market position, recognised for its commitment to quality and patient-centric approaches. With a legacy of innovation and a focus on sustainable healthcare, Novartis continues to play a pivotal role in the advancement of medical science in Bangladesh.
DitchCarbon Score
How does Novartis (Bangladesh) Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novartis (Bangladesh) Limited's score of 62 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novartis (Bangladesh) Limited's reported carbon emissions
Novartis (Bangladesh) Limited currently does not have available carbon emissions data, as no specific figures have been provided. Consequently, there are no reported emissions for the most recent year, nor are there any details regarding Scope 1, 2, or 3 emissions. In terms of climate commitments, there are no documented reduction targets or initiatives outlined in the available information. This absence of data suggests that Novartis (Bangladesh) Limited may still be in the process of establishing or formalising its climate strategy and reduction goals. As the pharmaceutical industry increasingly prioritises sustainability, it is essential for companies like Novartis to develop clear climate commitments and measurable targets to align with global efforts to mitigate climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novartis (Bangladesh) Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
